

10/652334

C9e
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Certificate

FEB 16 2006

of Correction

Patentee: Peltz, et al.

Patent No.: 6,989,256 B2

Issued: January 24, 2006

Docket: 1368-12 CON

For: SUBFAMILY OF RNA HELICASES
WHICH ARE MODULATORS OF THE
FIDELITY OF TRANSLATION
TERMINATION AND USES
THEREOF

Dated: February 8, 2006

I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to: Commissioner for
Patents, Alexandria, VA 22313-1450

Date: February 8, 2006

Signature: K.J. Goodhand/

K.J. Goodhand

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Decision and Certificate of Correction
Branch of the Patent Issue Division

REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT
FOR PTO MISTAKE UNDER 37 CFR §1.322(a) and
APPLICANT'S MISTAKE UNDER 37 C.F.R. §1.323

Sir:

Patentee respectfully requests correction of the mistakes in the above-referenced U.S.
Patent No. 6,989,256 B2. In particular:

At column 3, line 33, the printed patent incorrectly reads "...to MATT1...". At page 5,
line 2 of the original specification as filed, however, the text reads ---to MTT1---.

At column 13, line 15, the printed patent incorrectly reads "...for MTT 1 agonists...". At
page 22, line 9 of the original specification as filed, however, the text reads ---for MTT1
agonists---.

At column 27, line 10, the printed patent incorrectly reads "...transcripts in a cell in a cell, said...". At page 46, line 2 of the original specification as filed, however, the text reads --...transcripts in a cell, said...--.

These mistakes are a result of errors on the part of the U. S. Patent and Trademark Office. Appropriate correction is therefore respectfully requested.

Patentee further requests that at column 3, line 22 the printed patent incorrectly reads "...composition which is which modulates...". The patent should read --...composition which modulates...--.

At column 6, line 3, the printed patent incorrectly reads "...with the a translation...". The patent should read --...with the translation...--.

At column 6, line 38, the printed patent incorrectly reads "...termination The results...". The patent should read --...termination. The results...--.

At column 12, line 26, the printed patent incorrectly reads "...before tranfection; and...". The patent should read --...before transfection; and...--.

At column 14, line 11, the printed patent incorrectly reads "...effect on NMD between ...". The printed patent should read --...effect on NMRD between...--.

At column 17, line 37, the printed patent incorrectly reads "...provides method for...". The printed patent should read --...provides a method for...--.

At column 18, line 53, the printed patent incorrectly reads "...number of inherited disease in which...". The printed patent should read --...number of inherited diseases in which...--.

At column 18, lines 53-55, the printed patent incorrectly reads "...in which nonsense mutations cause the disease state and in which nonsense mutations cause the disease state...". The printed patent should read --...in which nonsense mutations cause the disease state...--.

At column 22, line 18, the printed patent incorrectly reads "...state involving defective the protein...". The printed patent should read --...state involving the defective protein...--.

At column 22, lines 56-57, the printed patent incorrectly reads "...conserved among member of this group...". The printed patent should read --...conserved among members of this group...--.

At column 27, line 22, the printed patent incorrectly reads "...administering to a subject administering to a subject a...". The printed patent should read --...administering to a subject a ...--.

At column 27, line 29, the printed patent incorrectly reads "...treating a patient having or at risk of having early stage as...". The printed patent should read --...treating a patient having or at risk of having early stage disease as...--.

At column 27, lines 31-32, the printed patent incorrectly reads "...etiology associated with a defective,...". The printed patent should read --...etiology associated with a defective complex,...--.

At column 37, line 24, the printed patent incorrectly reads "...in translation termination The results...". The printed patent should read --...in translation termination. The results...--.

At column 37, line 65, the printed patent incorrectly reads "...have been shown unwind both DNA and RNA...". The printed patent should read --...have been shown to unwind both DNA and RNA...--.

These mistakes are typographical errors on the part of the Applicant and are believed to be of minor character. Appropriate correction is therefore respectfully requested.

Attached herewith in duplicate please find a fully completed Form PTO-SB-44 with at least one copy being suitable for printing. The requisite fee of \$100.00, as required by 37 C.F.R. §1.20(a), should be charged to Deposit Account No. 08-2461.


The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication, or credit any overpayment, to Deposit Account No. 08-2461. Such authorization includes authorization to charge fees for extensions of time, if any, under 37 C.F.R § 1.17 and also should be treated as a constructive petition for an extension of time in this reply or any future reply pursuant to 37 C.F.R. § 1.136.

Please forward the Certificate of Correction to:

Daniel A. Scola, Jr., Esq.
Hoffmann & Baron, LLP
6900 Jericho Turnpike
Syosset, NY 11791

Any questions concerning this communication should be directed to the undersigned, who can be reached by telephone at (973) 331-1700.

Respectfully submitted,



Gloria K. Szakiel
Registration No. 45,149
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791-4407
(973) 331-1700

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,898,256 B2

DATED : January 24, 2006

INVENTOR(S) : Peltz, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 3, line 22, the printed patent should read "...composition which modulates...".

At column 3, line 33, the printed patent should read "...to MTT1...".

At column 6, line 3, the printed patent should read "...with the translation...".

At column 6, line 38, the printed patent should read "...termination. The results...".

At column 12, line 26, the printed patent should read "...before transfection; and...".

At column 13, line 15, the printed patent should read "...for MTT1 agonists...".

At column 14, line 11, the printed patent should read "...effect on NMRD between...".

At column 17, line 37, the printed patent should read "...provides a method for...".

At column 18, line 53, the printed patent should read "...number of inherited diseases in which...".

At column 18, lines 53-55, the printed patent should read "...in which nonsense mutations cause the disease state...".

At column 22, line 18, the printed patent should read "...state involving the defective protein...".

At column 22, lines 56-57, the printed patent should read "...conserved among members of this group...".

At column 27, line 10, the printed patent should read "...transcripts in a cell, said...".

At column 27, line 22, the printed patent should read "...administering to a subject a...".

At column 27, line 29, the printed patent should read "...treating a patient having or at risk of having early stage disease as...".

At column 27, lines 31-32, the printed patent should read "...etiology associated with a defective complex,...".

At column 37, line 24, the printed patent should read "...in translation termination. The results...".

At column 37, line 65, the printed patent should read "...have been shown to unwind both DNA and RNA...".

MAILING ADDRESS OF SENDER: Daniel A. Scola, Jr.
Hoffmann & Baron, LLP
6900 Jericho Turnpike
Syosset, NY 11791

PATENT NO. 6,989,256 B2

No. of additional copies

→ 1

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : 6,898,256 B2

DATED : January 24, 2006

INVENTOR(S) : Peltz, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 3, line 22, the printed patent should read "...composition which modulates..."

At column 3, line 33, the printed patent should read "...to MTT1..."

At column 6, line 3, the printed patent should read "...with the translation..."

At column 6, line 38, the printed patent should read "...termination. The results..."

At column 12, line 26, the printed patent should read "...before transfection; and..."

At column 13, line 15, the printed patent should read "...for MTT1 agonists..."

At column 14, line 11, the printed patent should read "...effect on NMRD between..."

At column 17, line 37, the printed patent should read "...provides a method for..."

At column 18, line 53, the printed patent should read "...number of inherited diseases in which..."

At column 18, lines 53-55, the printed patent should read "...in which nonsense mutations cause the disease state..."

At column 22, line 18, the printed patent should read "...state involving the defective protein..."

At column 22, lines 56-57, the printed patent should read "...conserved among members of this group..."

At column 27, line 10, the printed patent should read "...transcripts in a cell, said..."

At column 27, line 22, the printed patent should read "...administering to a subject a..."

At column 27, line 29, the printed patent should read "...treating a patient having or at risk of having early stage disease as..."

At column 27, lines 31-32, the printed patent should read "...etiology associated with a defective complex..."

At column 37, line 24, the printed patent should read "...in translation termination. The results..."

At column 37, line 65, the printed patent should read "...have been shown to unwind both DNA and RNA..."

MAILING ADDRESS OF SENDER: Daniel A. Scola, Jr.
Hoffmann & Baron, LLP
6900 Jericho Turnpike
Syosset, NY 11791

PATENT NO. 6,898,256 B2

No. of additional copies

 1

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.